U.S. Markets closed

Chimerix, Inc. (CMRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.63-0.31 (-4.47%)
At close: 4:00PM EDT

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919 806 1074
http://www.chimerix.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees54

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael A. ShermanCEO, Pres & Director1.11MN/A1966
Mr. Michael T. Andriole M.B.A.Chief Bus. Officer, Sec. & CFO657.35kN/A1973
Dr. Allen S. Melemed M.B.A., M.D.Chief Medical Officer508.92kN/AN/A
Mr. David JakemanExec. Director of Fin. & Accounting and Principal Accounting OfficerN/AN/A1977
Dr. Roy W. WareChief Manufacturing & Technology OfficerN/AN/AN/A
Dr. Randall LanierChief Science OfficerN/AN/AN/A
Ms. Michelle LaSpalutoVP of Strategic Planning & Investor RelationsN/AN/AN/A
Dr. Michael A. AlrutzSr. VP, Gen. Counsel & Corp. Sec.N/AN/A1970
Dr. Joshua E. AllenChief Technology Officer of ImipridonesN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Corporate Governance

Chimerix, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.